(Health Korea News / Chang-yong Lee) JW New Drug announced on the 7th that its net profit in the third quarter (separate basis) achieved KRW 6.1 billion, a 216.9% surge compared to the same quarter last year (KRW 1.9 billion) through provisional business performance disclosure.
During the same period, operating profit also increased by 212.3% compared to the same period last year (KRW 2.6 billion), reaching KRW 8.1 billion. Sales amounted to KRW 31.5 billion, a 20.1% increase from the previous year (KRW 26.2 billion).
As a result, JW New Drug recorded cumulative sales of KRW 76.9 billion and cumulative operating profit of KRW 12.9 billion in the first to third quarters, receiving an increase of 2.5% and 89.8%, respectively, compared to the same period last year. Cumulative net profit was KRW 9.2 billion, successfully turning into a surplus compared to the same period last year.
(JW Shinyak’s provisional operating performance for the third quarter of 2024 on a separate basis) (Unit: KRW million, %)
|
division(unit: million won%) |
Current performance |
previous year performance |
Increase/decrease amount compared to the previous quarter (rate of increase/decrease) |
Performance for the same period last year |
Increase/decrease amount compared to the same period last year (rate of increase/decrease) |
|
|
(24year 3branch) |
(24year 2branch) |
(23year 3branch) |
||||
|
take |
Performance of the year |
31,512 |
21,631 |
9,881(45.7%) |
26,237 |
5,275(20.1%) |
|
Cumulative performance |
76,935 |
– |
– |
75,078 |
1,857(2.5%) |
|
|
operating profit |
Performance of the year |
8,126 |
1,887 |
6,239(330.6%) |
2,602 |
5,524(212.3%) |
|
Cumulative performance |
12,889 |
– |
– |
6,790 |
6,099(89.8%) |
|
|
net profit |
Performance of the year |
6,053 |
1,196 |
4,857(406.0%) |
1,910 |
4,143(216.9%) |
|
Cumulative performance |
9,171 |
– |
– |
-32,531 |
Turn into surplus |
|
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
